Instrument Inactif

Autres langues ACLS THER Nasdaq

Actions

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

06/08	Aclaris Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
06/08	Aclaris Therapeutics, Inc. obtient la désignation " Fast Track » pour le modzatinib (ATI-2138) dans le traitement du lichen plan modéré à sévère	CI

Autres langues

06/08	Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib
06/08	Aclaris Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
06/08	Aclaris Therapeutics, Inc. Receives Fast Track Designation For Modzatinib (ATI-2138) For Moderate To Severe Lichen Planus
06/08	Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M
06/08	Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss
06/08	Aclaris: Q2 Earnings Snapshot
06/08	Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 2500 Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 2000 Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000E Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000 Growth Benchmark
22/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index
28/05	Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
08/05	Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08/05	Aclaris Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Aclaris: Q1 Earnings Snapshot
07/05	Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
28/04	Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055
28/04	Aclaris Therapeutics : ATI-052 full SAD/MAD results + ATI-2138 update (44ce59)
28/04	Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
28/04	Aclaris Therapeutics Announces Positive Full Top Line First-In-Human Results from Phase 1A Healthy Volunteer Clinical Trial of ATI-052 and Lichen Planus as Lead Indication for ATI-2138